Secure Asset Management LLC reduced its position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) by 9.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,899 shares of the company’s stock after selling 6,523 shares during the period. Oruka Therapeutics accounts for about 0.9% of Secure Asset Management LLC’s holdings, making the stock its 29th biggest holding. Secure Asset Management LLC owned approximately 0.10% of Oruka Therapeutics worth $6,272,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Oruka Therapeutics in the 2nd quarter valued at about $474,916,000. Viking Global Investors LP acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $51,280,000. Deep Track Capital LP increased its holdings in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after buying an additional 735,983 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Oruka Therapeutics by 38.1% during the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after buying an additional 676,865 shares during the period. Finally, RTW Investments LP raised its position in shares of Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after buying an additional 112,499 shares during the period. 56.44% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages recently weighed in on ORKA. Wedbush reiterated an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Guggenheim restated a “buy” rating and issued a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Finally, Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.
Insider Transactions at Oruka Therapeutics
In other news, CEO Lawrence Otto Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $111.84, for a total value of $782,880.00. Following the completion of the sale, the insider owned 32,718 shares in the company, valued at $3,659,181.12. This represents a 17.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 158,116 shares of company stock valued at $13,523,783. Corporate insiders own 23.49% of the company’s stock.
Oruka Therapeutics Stock Performance
NASDAQ:ORKA opened at $92.11 on Wednesday. Oruka Therapeutics, Inc. has a fifty-two week low of $14.66 and a fifty-two week high of $115.51. The company has a 50 day moving average price of $94.92 and a 200 day moving average price of $68.59. The stock has a market capitalization of $6.10 billion, a P/E ratio of -45.37 and a beta of -0.34.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Research analysts forecast that Oruka Therapeutics, Inc. will post -2.33 earnings per share for the current fiscal year.
About Oruka Therapeutics
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Recommended Stories
- Five stocks we like better than Oruka Therapeutics
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
